Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association - 1 Jan 2000

Oh Myung Jin, Lee Heon Ju

Abstract excerpt

BACKGROUND/AIMS: Hepatitis B virus (HBV) rtA181V/T mutants developed by long-term nucleos(t) ide analogue therapy are known to present cross-resistance for other nucleos (t) ide analogues, except entecavir (ETV). Some studies reported that HBV rtA181V/T mutants could induce cross-resistance to ETV and showed incomplete response as well as persistence of HBV DNA, despite rescue therapy by ETV. This study aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Therapy, Combination

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Organophosphonates

Source

Open in PubMed Open full text

Identifiers

PMID: 26831605
DOI: 10.4103/1319-3767.173757
PMCID: PMC4763527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.PMID 26831605Read ↗

Efficacy of Different Nucleoside Analog Rescue Therapies for Entecavir-Resistant Chronic Hepatitis B PatientsSemantic proximity Read ↗

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.Semantic proximity Read ↗

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.Semantic proximity Read ↗

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.Semantic proximity Read ↗

Characterization of novel entecavir resistance mutations.Semantic proximity Read ↗

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.Semantic proximity Read ↗

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.Semantic proximity Read ↗

Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases.Semantic proximity Read ↗

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.Semantic proximity Read ↗

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.Semantic proximity Read ↗

Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.Semantic proximity Read ↗

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.